Julie M Cunningham
Overview
Explore the profile of Julie M Cunningham including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
270
Citations
11976
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramachandran D, Tyrer J, Kommoss S, DeFazio A, Riggan M, Webb P, et al.
NPJ Genom Med
. 2024 Mar;
9(1):19.
PMID: 38443389
Survival from ovarian cancer depends on the resection status after primary surgery. We performed genome-wide association analyses for resection status of 7705 ovarian cancer patients, including 4954 with high-grade serous...
2.
Gersekowski K, Na R, Alsop K, Delahunty R, Goode E, Cunningham J, et al.
Cancer Epidemiol Biomarkers Prev
. 2024 Feb;
33(4):586-592.
PMID: 38300121
Background: Women with an inherited pathogenic variant in BRCA1 or BRCA2 have a greatly increased risk of developing ovarian cancer, but the importance of behavioral factors is less clear. We...
3.
Scotch M, Lauer K, Wieben E, Cherukuri Y, Cunningham J, Klee E, et al.
mSphere
. 2023 Oct;
8(6):e0023223.
PMID: 37882516
We analyzed over 22,000 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomes of patient samples tested at Mayo Clinic Laboratories during a 2-year period in the COVID-19 pandemic, which included...
4.
Wang C, Block M, Cunningham J, Sherman M, McCauley B, Armasu S, et al.
Cancer Epidemiol Biomarkers Prev
. 2023 Feb;
32(4):542-549.
PMID: 36790339
Background: Better understanding of prognostic factors in tubo-ovarian high-grade serous carcinoma (HGSC) is critical, as diagnosis confers an aggressive disease course. Variation in tumor DNA methylation shows promise predicting outcome,...
5.
Kang E, Weir A, Meagher N, Farrington K, Nelson G, Ghatage P, et al.
Cancer
. 2022 Dec;
129(5):697-713.
PMID: 36572991
Background: Cyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo-ovarian high-grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification and CCNE1 overexpression...
6.
Garsed D, Pandey A, Fereday S, Kennedy C, Takahashi K, Alsop K, et al.
Nat Genet
. 2022 Dec;
54(12):1853-1864.
PMID: 36456881
Fewer than half of all patients with advanced-stage high-grade serous ovarian cancers (HGSCs) survive more than five years after diagnosis, but those who have an exceptionally long survival could provide...
7.
Weir A, Kang E, Meagher N, Nelson G, Ghatage P, Lee C, et al.
Br J Cancer
. 2022 Nov;
128(1):137-147.
PMID: 36323878
Background: Recently, we showed a >60% difference in 5-year survival for patients with tubo-ovarian high-grade serous carcinoma (HGSC) when stratified by a 101-gene mRNA expression prognostic signature. Given the varied...
8.
Liu Y, Bhagwate A, Winham S, Stephens M, Harker B, McDonough S, et al.
BMC Med Genomics
. 2022 Sep;
15(1):195.
PMID: 36114500
Background: Formalin-fixed, paraffin-embedded (FFPE) tissues have many advantages for identification of risk biomarkers, including wide availability and potential for extended follow-up endpoints. However, RNA derived from archival FFPE samples has...
9.
Scotch M, Lauer K, Wieben E, Cherukuri Y, Cunningham J, Klee E, et al.
medRxiv
. 2022 Aug;
PMID: 35923324
SARS-CoV-2 has had an unprecedented impact on human health and highlights the need for genomic epidemiology studies to increase our understanding of virus evolution and spread, and to inform policy...
10.
He Y, Wei C, Sun Z, Cunningham J, Wang L, Wei Z, et al.
Precis Clin Med
. 2022 Jul;
5(3):pbac017.
PMID: 35875603
No abstract available.